BEGIN:VCALENDAR
VERSION:2.0
PRODID:Spatie calendar-links
BEGIN:VEVENT
UID:17744111b1d3597b30bf2367b69562c9
SUMMARY:HPB & TPL II\n\n
DTSTAMP;TZID=e:20230608T101500
DTSTART;TZID=e:20230608T101500
DTEND;TZID=e:20230608T114500
X-ALT-DESC;FMTTYPE=text/html:HPB & TPL II\n\n\n\nChair(s): B. Schmied\, St.Gallen (CH)\; K. Lehmann\, Zurich (CH)\n\nPresentations:\n\nFeasibility and safety of intraoperative bile duct clearance by sphincter of Oddi balloon dilatation: A prospective observational pilot study\nReferent(s): <span class="presenting-referent"><u>G. A. Prevost\, Chur (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">C. Huber\, Olten (CH)<span class="wp-referents-separator">\; </span>B. Schnell\, Bern (CH)<span class="wp-referents-separator">\; </span>D. Candinas\, Bern (CH)<span class="wp-referents-separator">\; </span>R. Wiest\, Bern (CH)<span class="wp-referents-separator">\; </span>B. Schnüriger\, Bern (CH)</span>\n\nManagement of cystic duct remnant and symptomatic common bile duct stones after laparoscopic gastric bypass with cholecystectomy\nReferent(s): <span class="presenting-referent"><u>M. Schaub\, Villars-sur-Glâne (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">A. Meyer\, Fribourg (CH)<span class="wp-referents-separator">\; </span>B. Egger\, Fribourg (CH)<span class="wp-referents-separator">\; </span>F. Cherbanyk\, Villars-sur-Glâne (CH)<span class="wp-referents-separator">\; </span>K. Burgmann\, Villars-sur-Glâne (CH)</span>\n\nOutcomes from Randomized Controlled Trials comparing Inpatient versus Outpatient Laparoscopic Cholecystectomy\nReferent(s): <span class="presenting-referent"><u>H. Teixeira\, Frauenfeld (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">M. Müller\, Frauenfeld (CH)<span class="wp-referents-separator">\; </span>P. Antony\, Frauenfeld (CH)<span class="wp-referents-separator">\; </span>F. Hauswirth\, Münsterlingen (CH)<span class="wp-referents-separator">\; </span>P. Probst\, Frauenfeld (CH)</span>\n\nNeoadjuvant treatment versus upfront surgery for primary resectable pancreatic cancer: an update meta-analysis of comparative studies\nReferent(s): <span class="presenting-referent"><u>R. Roesel\, Lugano (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">L. Bernardi\, Lausanne (CH)<span class="wp-referents-separator">\; </span>A. Cristaudi\, Lugano (CH)<span class="wp-referents-separator">\; </span>L. Deantonio\, Lugano (CH)<span class="wp-referents-separator">\; </span>S. de Dosso\, Lugano (CH)</span>\n\nObjective Research Priorities in Pancreatic Surgery – Results of a worldwide online expert survey\nReferent(s): <span class="presenting-referent"><u>M. Holze\, Heidelberg (DE)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">R. Klotz\, Heidelberg (DE)<span class="wp-referents-separator">\; </span>P. Antony\, Frauenfeld (CH)<span class="wp-referents-separator">\; </span>M. K. Diener\, Heidelberg (DE)<span class="wp-referents-separator">\; </span>P. Probst\, Frauenfeld (CH)</span>\n\nSpatially restricted tumor- and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer\nReferent(s): <span class="presenting-referent"><u>A. S. Wenning\, Bern (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">P. Aeschbacher\, Bern (CH)<span class="wp-referents-separator">\; </span>A. Perren\, Bern (CH)<span class="wp-referents-separator">\; </span>E. Karamitopoulou-Diamantis\, Bern (CH)<span class="wp-referents-separator">\; </span>B. Gloor\, Bern (CH)</span>\n\nThe questionable burden of AB0 incompatible kidney transplantation\nReferent(s): <span class="presenting-referent"><u>C. Berchtold\, Visp (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">K. Lehmann\, Zurich (CH)<span class="wp-referents-separator">\; </span>K. Hübel\, Zurich (CH)<span class="wp-referents-separator">\; </span>F. Roessler\, Zurich (CH)<span class="wp-referents-separator">\; </span>N. Graf\, Zurich (CH)<span class="wp-referents-separator">\; </span>P. Dutkowski\, Zurich (CH)<span class="wp-referents-separator">\; </span>T. F. Mueller\, Zurich (CH)<span class="wp-referents-separator">\; </span>O. de Rougemont\, Zurich (CH)</span>\n\nReal-time assessment of kidney allografts during HOPE using flavin mononucleotide (FMN) - a preclinical study.\nReferent(s): <span class="presenting-referent"><u>R. X. Sousa Da Silva\, Zurich (CH)</u></span><span class="wp-referents-separator">\; </span><span class="co-referent">T. Darius\, Brussels (BE)<span class="wp-referents-separator">\; </span>L. Mancina\, Zurich (CH)<span class="wp-referents-separator">\; </span>J. Eden\, Zurich (CH)<span class="wp-referents-separator">\; </span>K. Wernlé\, Zurich (CH)<span class="wp-referents-separator">\; </span>A. Ghoneima\, Leeds (GB)<span class="wp-referents-separator">\; </span>A. Barlow\, Leeds (GB)<span class="wp-referents-separator">\; </span>P. A. Clavien\, Zurich (CH)<span class="wp-referents-separator">\; </span>P. Dutkowski\, Zurich (CH)<span class="wp-referents-separator">\; </span>P. Kron\, Zurich (CH)</span>\n\n
LOCATION:Boston III\, Ground floor
END:VEVENT
END:VCALENDAR